------------------------------------------------------------
[link removed]


** HVTN 705 Vaccine Trial Ends—Join Sept 9 webinar to discuss next steps for field
------------------------------------------------------------
August 31, 2021

Dear Advocate,

Today Johnson & Johnson ([link removed]) and partners announced that the Imbokodo study ([link removed]) , a large-scale HIV vaccine proof-of-concept trial also known as HVTN 705/ HPX2008, did not significantly reduce the overall risk of HIV acquisition among over 2,600 women in five sub-Saharan African countries. The Adenovirus26-based mosaic vaccine regimen was shown to be safe. A companion study, the Phase III Mosaico
([link removed]) trial, will continue.

Read AVAC’s full statement here ([link removed]) about the results and what needs to happen next.

Register for a global webinar ([link removed]) , scheduled for September 9 at 10am ET to discuss this development and the implications for the HIV vaccine field.

We hope you will bring your questions and your passion. HIV continues to be a global threat. The field can and must learn from these trials and from the success of the COVID-19 vaccine enterprise, to explore new HIV vaccine strategies and bring a lasting end to the epidemic.

Best,
AVAC

============================================================
Forward This Issue Do you know someone who might be interested in receiving this newsletter?
** Forward > ([link removed])

Unsubscribe You're receiving this because you signed up for our newsletter. Not interested any longer?
** Unsubscribe > ([link removed])

Contact Us T: +1 212 796 6423
E: ** [email protected] (mailto:[email protected])
W: ** www.avac.org ([link removed])
** ([link removed])
** ([link removed])
** ([link removed])